Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-tRNA synthetases
Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
1. A therapeutic composition, comprising an isolated phenylalanyl-beta-tRNA synthetase (PheRS) polypeptide of about 100 to about 130 amino acids in length and comprising an amino acid sequence that is at least 95% identical to 100 or more contiguous amino acids of SEQ ID NO:53, wherein the polypeptide has an extracellular signaling activity and a solubility of at least about 5 mg/mL, and wherein the composition has a purity of at least about 95% on a protein basis and less than about 10 EU endotoxin/mg protein.
2. The therapeutic composition of claim 1 , wherein the PheRS polypeptide specifically binds to a binding partner to exert a physiological effect.
3. The therapeutic composition of claim 1 , wherein the PheRS polypeptide differs from SEQ ID NO:53 by substitution, deletion, and/or addition of about 0, 1, 2, 3, 4, or 5 amino acids, and wherein the altered PheRS polypeptide substantially retains an extracellular signaling activity of the unaltered polypeptide.
4. The therapeutic composition of claim 1 , wherein the PheRS polypeptide is fused to a heterologous polypeptide.
5. The therapeutic composition of claim 1 , wherein at least one moiety or a solid substrate is covalently or non-covalently attached to said polypeptide.
6. The therapeutic composition of claim 1 , wherein the PheRS polypeptide is fused to a pharmacokinetic (PK) property modifier.
7. A method of modulating a cellular activity of a cell, or protein, comprising contacting the cell or protein with a therapeutic composition of claim 1 .
8. The method of claim 7 , wherein the cell or protein is in a subject having a disease or disorder mediated by the dysregulation of the expression, activity or spatiotemporal location of a tRNA synthetase, comprising administering the therapeutic composition to the subject.
9. The method of claim 8 , wherein the disease is selected from cancer, neuropathy, diabetes, and inflammatory disorders.
10. The therapeutic composition of claim 3 , wherein the PheRS polypeptide differs from SEQ ID NO:53 by substitution, deletion, and/or addition of about 0, 1, 2, or 3 amino acids.
11. The therapeutic composition of claim 1 , wherein the PheRS polypeptide is up to about 120 amino acids in length and comprises SEQ ID NO:53 or a sequence at least 95% identical to SEQ ID NO:53.
12. The therapeutic composition of claim 11 , wherein the PheRS polypeptide comprises SEQ ID NO:53.